SYNB1891 + Atezolizumab
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 11/100
11
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Solid Neoplasm
Conditions
Metastatic Solid Neoplasm, Lymphoma
Trial Timeline
Dec 12, 2019 → Dec 9, 2021
NCT ID
NCT04167137About SYNB1891 + Atezolizumab
SYNB1891 + Atezolizumab is a phase 1 stage product being developed by Synlogic for Metastatic Solid Neoplasm. The current trial status is terminated. This product is registered under clinical trial identifier NCT04167137. Target conditions include Metastatic Solid Neoplasm, Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Solid Neoplasm were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04167137 | Phase 1 | Terminated |
Competing Products
20 competing products in Metastatic Solid Neoplasm